Novo Nordisk A/S's (NVO) Market Perform Rating Reaffirmed at BMO Capital Markets

Novo Nordisk A/S (NYSE:NVO - Get Free Report)'s stock had its "market perform" rating reiterated by equities research analysts at BMO Capital Markets in a report issued on Thursday, MarketBeat.com reports. They currently have a $64.00 target price on the stock, down from their prior target price of $105.00. BMO Capital Markets' target price indicates a potential upside of 9.63% from the company's current price.

A number of other analysts also recently commented on the company. Stifel Nicolaus downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating for the company. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, April 15th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of "Hold" and a consensus target price of $135.00.

Novo Nordisk A/S Stock Performance

Shares of NVO traded up $0.30 during trading hours on Thursday, reaching $58.38. 4,783,645 shares of the company traded hands, compared to its average volume of 5,976,147. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The business has a fifty day moving average price of $75.52 and a 200-day moving average price of $91.38. Novo Nordisk A/S has a 12-month low of $57.05 and a 12-month high of $148.15. The stock has a market capitalization of $261.98 billion, a P/E ratio of 17.74, a P/E/G ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Large investors have recently made changes to their positions in the stock. Bigelow Investment Advisors LLC purchased a new stake in Novo Nordisk A/S in the 1st quarter valued at $200,000. CWA Asset Management Group LLC increased its holdings in shares of Novo Nordisk A/S by 129.5% during the 1st quarter. CWA Asset Management Group LLC now owns 72,631 shares of the company's stock worth $5,043,000 after buying an additional 40,987 shares during the last quarter. MFA Wealth Advisors LLC lifted its holdings in Novo Nordisk A/S by 5.6% in the first quarter. MFA Wealth Advisors LLC now owns 6,441 shares of the company's stock valued at $447,000 after acquiring an additional 342 shares during the last quarter. PUREfi Wealth LLC increased its stake in Novo Nordisk A/S by 25.3% during the first quarter. PUREfi Wealth LLC now owns 3,700 shares of the company's stock worth $257,000 after acquiring an additional 747 shares during the last quarter. Finally, Essex Savings Bank grew its holdings in shares of Novo Nordisk A/S by 20.3% during the 1st quarter. Essex Savings Bank now owns 11,592 shares of the company's stock worth $805,000 after purchasing an additional 1,956 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.